Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer

摘要: Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of non-muscle invasive bladder cancer (NMIBC) for nearly 35 years; however, its use is still subject to controversy. The objective this paper review role BCG patients with NMIBC. Clinical trials, meta-analyses and guidelines related administration, safety efficacy were reviewed. Intravesical more effective than chemotherapy decreasing risk recurrence progression muscle disease; it associated local systemic side-effects. It gold standard at high progression. Maintenance required order achieve best therapeutic results; optimal dose, induction maintenance schedules, duration are unknown might be different each patient. Patients failing have a poor prognosis, cystectomy then recommended treatment. low should not receive BCG, because side effects. Intermediate-risk treated either or BCG; progression, recognized as choice. Further research urgently needed identify markers failure develop alternatives BCG.